Vol 27, No 2 (2022)
Case report
Published online: 2022-02-04

open access

Page views 4969
Article views/downloads 280
Get Citation

Connect on Social Media

Connect on Social Media

Fat transformation of the tissue of the single left kidney 10 years after treatment of renal cell carcinoma of both kidneys

Assel Zhumagulova1, Davran Arypzhanov1
Rep Pract Oncol Radiother 2022;27(2):381-386.


Renal cell carcinoma morbidity grows in most of countries. All over the world 200,000 new cases are diagnosed every year, and approximately 102,000 patients die of this disease, with an incidence of nearly nine cases per 100,000 inhabitants per year. That’s why, renal cell carcinoma is a challenging field in the current oncology research. Among urologic tumors, renal cell carcinoma ranks third in terms of incidence after prostate carcinoma and transitional cell carcinoma of the bladder. Renal cell carcinoma accounts for approximately 3% of adult malignancies and 90–95% of neoplasms arising from the kidney.

Bilateral renal cell carcinoma (BRCC) is a rare disease with poor prognosis which accounts for 2–6% of all cases of renal cell carcinoma. Only a few case reports and series with a small number of patients with bilateral renal cell carcinoma can be found in the literature.

We present an interesting clinical case of bilateral renal cell carcinoma with a total survival rate of more than 10 years.

Article available in PDF format

View PDF Download PDF file


  1. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol. 2008: 782381.
  2. Naito S, Tomita Y, Rha SY, et al. Kidney Cancer Working Group Report. Japan J Clin Oncol. 2010; 40(Suppl 1): i51–i56.
  3. Joshi A, Anand A, Prabhash K, et al. Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian J Cancer. 2017; 54(4): 601–604.
  4. Indicators of the oncology service of the Republic of Kazakhstan for 2018 (statistical and expert data). KazIOR, Almaty 2019: 9–14.
  5. Jonasch E. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. J Natl Compr Canc Netw. 2019; 17(5.5): 587–589.
  6. Zincke H, Swanson S. Bilateral Renal Cell Carcinoma: Influence of Synchronous and Asynchronous Occurrence on Patient Survival. J Urology. 1982; 128(5): 913–915.
  7. Shaplygin LV, Furashov DV, Sergienko NF. Experience in the treatment of patients with synchronous kidney cancer. Proceedings of the First Congress of Oncologists of the CIS, Alma-Ata 2006: 144–145.
  8. Trapeznikova MF, Bazaev VV, Bychkova NV, Vashchenko AV. The role of angiography in the modern diagnosis of kidney tumors. Proceedings of the First Congress of Oncologists of the CIS, Alma-Ata 2006: 127.
  9. Picciochi A, Ugo D, Bruni V, et al. Synchronous bilateral renal cell carcinoma. J Urol. 1987; 93(9–10): 517–521.
  10. Topley M, Novick AC, Montie JE. Langzeitergebnisse nach partieller Nephrektomie bei lokalisiertem Nierenadenokarzinom. J Urol. 1994; 131(6): 1050–1052.
  11. Smith RB. The treatment of bilateral renal cell carcinoma in the solitary kidney. Tumors of the Kidney. Baltimore-London-Los Angeles-Sidney 1986: 353–360.
  12. Suvorova YuV, Tarazov PG. Malignant tumors of the single kidney: the role of selective arterial embolization. Proceedings of the First Congress of Oncologists of the CIS, Alma-Ata 2006: 126.
  13. Gantsev S, Yun V, Zhumagulova AK, et al. Embolization of the Renal Artery in Combined Treatment of Stage IV Kidney Cancer. Creative Surg Oncol. 2020; 10(3): 205–211.
  14. Nesterov SN, Viller AG, Khanaliyev BV, et al. Application of endovascular superselective embolization in treatment of renal artery-defense fistula. Bull Pirogov National Med Surg Center. 2018; 13(3): 143–144.
  15. Laurent A, Moine L. [The new biomaterials of embolization: the shift to degradable]. Med Sci (Paris). 2017; 33(1): 25–31.
  16. Ye Y, Ren Y, Zeng H, et al. Characterization of Calibrated Gelatin Sponge Particles in a Rabbit Renal Embolization Model. Cardiovasc Intervent Radiol. 2019; 42(8): 1183–1191.

Reports of Practical Oncology and Radiotherapy